Abstract
The aim of this study was to investigate the prognostic impact of baseline tumor burden and loci on the efficacy of first line renal cancer treatment with sunitinib. Baseline and on-treatment CT scans were evaluated. Both the Kaplan-Meier and Weibull modelling survival estimators have been used to describe sunitinib treatment response. Logistic regression was used to confirm associations between tumor site, burden and survival. Additionally, analysis of the metastases co-occurrence was conducted using the Bayesian inference on treated and external validation cohorts. 100 patients with metastatic clear cell renal cell carcinoma were treated with sunitinib in this study. Presence of metastases in the abdominal region (HR = 3.93), and the number of brain metastases correlate with shorter PFS, while the presence of thoracic metastases (HR = 0.47) with longer PFS. Localization of metastases in the abdominal region significantly impacts risk of metastases development in other locations including bone and brain metastases. Biology of metastases, in particular their localization, requires further molecular and clinical investigation.
Highlights
Www.nature.com/scientificreports histology; and 5.3 months – in those with brain metastases; but list of predictive and prognostic factors for that treatment is still not fully defined[3,4,5]
The findings of this analysis provide insight into how TB and its characteristics, i.e. metastases location, influence outcomes of ccRCC patients treated with sunitinib
Our analysis of total TB impact on sunitinib efficacy in RCC patients is in accordance with data available for everolimus from RECORD-3 trial, in which the baseline sum of longest tumor diameters was reported as a predictive factor of OS30
Summary
Www.nature.com/scientificreports histology; and 5.3 months – in those with brain metastases; but list of predictive and prognostic factors for that treatment is still not fully defined[3,4,5]. It was observed that some patients progress rapidly during treatment, while others achieve stable disease for a long time[10]. Overall, measuring the size of tumors remains the simplest way to estimate the severity of disease and possibly predict response/progression on treatment in routine clinical practice world-wide. Our research hypothesis was that prognosis that relies on general change of tumor size needs to be supplemented with additional factors/biomarkers to predict patients’ response to treatment. The aim of the present study was to investigate the possible prognostic role of baseline tumor burden, including metastasis location, metastases co-localization and subsequent local and general tumor shrinkage (depth of remission) in a homogeneous group of patients treated with sunitinib in first line treatment in clinical practice, outside of clinical trials. Reduction of tumor size was measured according to percentage change in the sum of the largest diameter of target lesions
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
